Funder
Associazione Italiana per la Ricerca sul Cancro
European Hematology Association
Fondazione Telethon
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference36 articles.
1. Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, et al. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Med. 2020;111:478–90. https://pubmed.ncbi.nlm.nih.gov/32955830/.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–7.
3. Liew E, Atenafu EG, Schimmer AD, Yee KWL, Schuh AC, Minden MD, et al. Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leuk Res. 2012;36:1517–20. http://www.sciencedirect.com/science/article/pii/S0145212612003529.
4. Kim IS. Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation. Blood Res. 2020;55:S19–26. https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2020.S004.
5. Sikich N, Soulodre C, Sadasook N, Sleeman A, Verhey J. Citation Health Quality Ontario. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser. Ont Health Technol Assess Ser. 2016;16:1–52.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献